BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31612912)

  • 21. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.
    Ross JS; Wang K; Elkadi OR; Tarasen A; Foulke L; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Chmielecki J; Ali SM; Elvin J; Morosini D; Miller VA; Stephens PJ
    J Clin Pathol; 2014 Sep; 67(9):772-6. PubMed ID: 24978188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
    Zhang J; Zhou N; Deng H; Chen X; Chen Q; Wang Q; Sun L; Wen Y; Cao X; Luo Z; Zhang J; Zhu W; Guo L
    Lung Cancer; 2023 Apr; 178():11-19. PubMed ID: 36758321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Su Z; Wang Z; Ni X; Duan J; Gao Y; Zhuo M; Li R; Zhao J; Ma Q; Bai H; Chen H; Wang S; Chen X; An T; Wang Y; Tian Y; Yu J; Wang D; Xie XS; Bai F; Wang J
    Clin Cancer Res; 2019 Aug; 25(16):5049-5060. PubMed ID: 31113842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.
    Jin W; Lei Z; Xu S; Fachen Z; Yixiang Z; Shilei Z; Tao G; Zhe S; Fengzhou L; Su WH; Chundong G
    Biomed Res Int; 2021; 2021():3609028. PubMed ID: 33880365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
    Lyu Q; Zhu W; Wei T; Ding W; Cao M; Wang Q; Guo L; Luo P; Zhang J
    Cancer Med; 2021 Nov; 10(21):7863-7876. PubMed ID: 34564955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
    Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
    Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer.
    Li L; Tang S; Yin JC; Dong L; Yang Z; Liu Y; Ma J; Chang P; Pang J; Bao H; Mu D; Zheng X; Aishajiang R; He K; Zhang S; Ni M; Wu X; Wang X; Shao Y; Wang J; Ge H; Yu J; Yuan S
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1165-1176. PubMed ID: 34942313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
    Bi N; Cao J; Song Y; Shen J; Liu W; Fan J; He J; Shi Y; Zhang X; Lu N; Zhan Q; Wang L
    PLoS One; 2014; 9(3):e91388. PubMed ID: 24637927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
    Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity.
    Ou SH; Ziogas A; Zell JA
    J Thorac Oncol; 2009 Jan; 4(1):37-43. PubMed ID: 19096304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.
    Fu M; Feng C; Wang J; Guo C; Wang Y; Gao R; Wang J; Zhu Q; Zhang X; Qi J; Zhang Y; Bian Y; Wang Z; Fang Y; Cao L; Hong B; Wang H
    Clin Exp Med; 2024 May; 24(1):99. PubMed ID: 38748269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients.
    Hong X; Xu Q; Yang Z; Wang M; Yang F; Gao Y; Zhou F; Wang L; Liu B; Chen G
    Clin Respir J; 2018 Feb; 12(2):433-447. PubMed ID: 27460525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
    Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
    Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
    Park S; Lee H; Lee B; Lee SH; Sun JM; Park WY; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Sep; 14(9):1640-1650. PubMed ID: 31125737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.